



## **DBV Technologies to Present at the 2015 Leerink Partners Global Healthcare Conference in New-York (USA)**

**BAGNEUX, France, February 3, 2015** - DBV Technologies, (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced that Mr. David Schilansky, Chief Operating Officer, and Mr. Charles Ruban, Chief Development Officer, will present at the 2015 Leerink Partners Global Healthcare Conference on Wednesday, February 11th at 1:50pm ET at the Waldorf Astoria Hotel in New York, NY.

A live audio webcast of the presentation will be available on the Investor Relations section of the company's website, <http://www.dbv-technologies.com/en/investor-relations>. A replay of the presentation will be available on DBV's website within 48 hours after the event.

### **About DBV Technologies**

DBV Technologies is developing Viaskin<sup>®</sup>, an innovative new approach to the treatment of allergies – a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus considerably lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products candidates: Viaskin<sup>®</sup> Peanut and Viaskin<sup>®</sup> Milk. The clinical development program for Viaskin<sup>®</sup> Peanut has received Fast Track designation from the US Food and Drug Administration.

DBV Technologies shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT).

### **Forward Looking Statements**

This press release contains forward-looking statements. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the French Autorité des Marchés Financiers and the Registration Statement filed with the Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release, whether as a result of new information, future events or circumstances or otherwise..



### **DBV Technologies Contacts**

#### **Susanna Mesa**

VP Finance, US Investor Relations & Strategy

Tel. : +1 917-346-3447

[susanna.mesa@dbv-technologies.com](mailto:susanna.mesa@dbv-technologies.com)

#### **Nathalie Donne**

Director, Corporate Communication & Business Development

Tel. : +33(0)1 55 42 78 72

[nathalie.donne@dbv-technologies.com](mailto:nathalie.donne@dbv-technologies.com)

### **DBV IR and Media Contacts**

#### **Rooney & Associates**

Media Relations

Marion Janic

Tel. : +1-212-223-4017

[mjanic@rooneyco.com](mailto:mjanic@rooneyco.com)